Objective:

To provide an overview of current methods and applications of stem cell therapy in retinal diseases, particularly age-related macular degeneration (AMD) and retinitis pigmentosa (RP), highlighting their significance in vision restoration.

Key Findings:

• Stem cell therapies have shown promise in treating AMD and RP by replacing lost or dysfunctional retinal cells, with some trials reporting stabilization or improvement in vision.
• Clinical trials indicate safety and potential efficacy of RPE cell transplants, with some patients experiencing stabilization or improvement in vision, such as in the studies by Mandai et al and da Cruz et al.
• Challenges remain, including immune rejection, the need for effective delivery methods, and the variability in patient responses.

Interpretation:

Stem cell therapy represents a transformative approach in ophthalmology, with the potential to restore vision in previously incurable retinal diseases, although further research is necessary to enhance efficacy, address challenges, and ensure long-term safety.

Limitations:

• Immune rejection remains a significant challenge, particularly with allogeneic grafts, as evidenced by the need for immunosuppression in clinical trials.
• Current studies often have small sample sizes and limited follow-up durations, which may affect the reliability of the findings.

Conclusion:

While stem cell therapies for retinal degenerations show significant promise, ongoing research is essential to optimize techniques, improve patient outcomes, and address the challenges identified in clinical trials.